GlucoTrackGCTK
GCTK
About: GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
Employees: 11
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
43% more funds holding
Funds holding: 7 [Q3] → 10 (+3) [Q4]
0.71% more ownership
Funds ownership: 1.0% [Q3] → 1.71% (+0.71%) [Q4]
23% less capital invested
Capital invested by funds: $133K [Q3] → $103K (-$30.2K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for GCTK.
Financial journalist opinion
Based on 3 articles about GCTK published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.
Neutral
GlobeNewsWire
3 weeks ago
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
Neutral
GlobeNewsWire
4 weeks ago
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. “2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company.
Neutral
GlobeNewsWire
1 month ago
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference
Neutral
GlobeNewsWire
2 months ago
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
Neutral
GlobeNewsWire
2 months ago
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is $1.15, The gross proceeds of the public offering are expected to be approximately $3.0 million before deducting agent placement fees and offering expenses. The closing of the public offering is expected to occur on or about February 5, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
The study met its primary endpoint with no procedure or device related serious adverse events reported The study met its primary endpoint with no procedure or device related serious adverse events reported
Neutral
GlobeNewsWire
3 months ago
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
Neutral
GlobeNewsWire
3 months ago
Glucotrack Announces ISO 13485:2016 Certification
ISO Certification highlights commitment to quality for continuous blood glucose monitor ISO Certification highlights commitment to quality for continuous blood glucose monitor
Neutral
GlobeNewsWire
3 months ago
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
Charts implemented using Lightweight Charts™